AUSTRALIAN Public Assessment Reports (AusPARs) have now been posted for three more products.
Janssen Cilag's spondyloarthritis treatment Simponi (golimumab) has had its indications extended under specific conditions; ERA Consulting's Brenzys (etanercept - rch) has been approved as a new biological entity for treatment of several arthritic and psoriatic conditions; and rheumatoid arthritis treatment Cimzia (certolizumab pegol) has been approved for extended indications.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jul 17
